Tag: Isocarboxazid

Marplan (isocarboxazid) is a type of antidepressant medication classified as a monoamine oxidase inhibitor (MAOI) that is primarily used to treat major depressive disorder, particularly in patients who have not responded to other forms of antidepressant therapy. Due to its significant risks and interactions, it is not typically considered a first-line treatment.

Over 20 million adults experience major depressive episodes annually in the U.S.. For those who haven't found relief with common medications, **what does isocarboxazid treat**? Isocarboxazid is a potent monoamine oxidase inhibitor (MAOI) reserved for treatment-resistant depression and specific anxiety disorders.

First approved by the FDA in 1959, Marplan is an older-generation antidepressant known generically as isocarboxazid. Its use has declined over time due to significant side effect and interaction risks, but it remains an option for patients with severe depression who have not responded to other treatments.

Isocarboxazid (brand name Marplan), an older antidepressant approved in the U.S. in 1959, is in the class of medications called monoamine oxidase (MAO) inhibitors. It is not considered a first-line treatment for depression due to its complex dietary and drug interactions, but it can be highly effective for those who have not responded to other antidepressants.

First approved by the FDA in 1959, the monoamine oxidase inhibitor (MAOI) Marplan (isocarboxazid) is, according to its manufacturer, still available for prescription. However, its history includes periods of limited availability and supply chain issues, which can cause confusion for patients and prescribers.

Isocarboxazid is a monoamine oxidase inhibitor (MAOI) that works by altering the brain's chemical balance to help lift mood. While it is a potent and effective antidepressant, its use requires strict dietary and medication precautions due to potentially dangerous interactions.